Patents by Inventor Markus MOHRS

Markus MOHRS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL10 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20250333464
    Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy.
    Type: Application
    Filed: November 22, 2024
    Publication date: October 30, 2025
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jie DAI, Maria del Pilar MOLINA-PORTELA, Ella IOFFE, Markus MOHRS
  • IL10 agonists and methods of use thereof
    Patent number: 12187772
    Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy and uses thereof. Certain IL10 agonists disclosed herein comprise an IgG Fc domain, a linker moiety, and an IL10 moiety.
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: January 7, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jie Dai, Maria del Pilar Molina-Portela, Ella Ioffe, Markus Mohrs
  • NOVEL IL10 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20230279070
    Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy.
    Type: Application
    Filed: April 28, 2023
    Publication date: September 7, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jie DAI, Maria del Pilar MOLINA-PORTELA, Ella IOFFE, Markus MOHRS
  • IL10 agonists and methods of use thereof
    Patent number: 11673930
    Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy. IL10 agonists disclosed herein comprise an IgG Fc domain, a linker moiety, and an IL10 moiety.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: June 13, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Jie Dai, Maria del Pilar Molina-Portela, Ella Ioffe, Markus Mohrs
  • COMBINATION OF CHECKPOINT INHIBITORS AND AN ONCOLYTIC VIRUS FOR TREATING CANCER
    Publication number: 20230139492
    Abstract: This disclosure relates to novel triple combination therapies of an oncolytic virus, a PD-1 pathway inhibitor, and a CTLA4 inhibitor for treating or inhibiting the growth of a tumor in a patient with cancer.
    Type: Application
    Filed: July 18, 2022
    Publication date: May 4, 2023
    Inventors: Saida Dadi-Mehmetaj, Markus Mohrs, Gavin Thurston
  • NOVEL IL10 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20210355184
    Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy.
    Type: Application
    Filed: May 11, 2021
    Publication date: November 18, 2021
    Inventors: Jie DAI, Maria del Pilar MOLINA-PORTELA, Ella IOFFE, Markus MOHRS